Zarrabian says Kintara, along with Kazia Therapeutics Limited (ASX:KZA) (NASDAQ:KZIA) and its drug paxalisib, will collaborate with the Global Coalition for Adaptive Research and are entering the GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) trial that opened in July and has screened more than 370 patients to date.
Kintara Therapeutics and Kazia Therapeutics begin trial to treat deadly brain cancer, glioblastoma
Quick facts: Kintara Therapeutics
Price: 1.71 USD
Market Cap: $52.37 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE